Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Study Examines Link Between Stress at Work and Cancer

      July 5, 2017
      By Brielle Urciuoli
      Article

      The risk of developing certain types of cancer can be increased by exposure to work-related stress.

      Study Examines Link Between Stress at Work and Cancer

      Study Examines Link Between Stress at Work and Cancer

      Extended exposure to work-related stress may increase the risk of developing certain kinds of cancers, according to findings of a study by researchers from the University of Quebec and University of Montreal.

      The study examined 3103 men from 11 different workplaces who developed cancer and compared them with 512 population controls.

      They found that employment in at least 1 stressful job increased the odds of lung, colon, bladder, rectal, and stomach cancer, and a duration-response trend was seen for cancers of the lung, colon, rectum, stomach, and non-Hodgkin lymphoma.

      “Prolonged exposure to perceived stress at work was associated with greater odds of cancer at 5 of 11 sites,” noted the authors.

      Prolonged exposure, according to the authors, was anything over 15 years. There was no association between stress exposure for less than 15 years and cancer risk.

      Previous research has shown that stress can have detrimental health effects, but few, if any, studied work-related stress and its specific impact on odds of developing cancer.

      To determine if there was a correlation, participants completed questionnaires to report whether they had frequent anxiety, depression, or troubling sleeping at least once a week for 6 months. These were noted as the “psychological symptoms.” Participants were also asked about other factors such as their lifestyle and socioeconomic status. The second part of the questionnaire specifically asked about their career, company and job description, as well as their perceived anxiety they experience from work.

      Careers with the most men reporting being stressed included: firefighters (40%); aerospace engineers (31%); and motor vehicle, rail transport mechanics, and repairmen (28%).

      As for socioeconomic status and stress, the study found that “men in the upper category of perceived stress duration (>30 years) had the highest family income, were the heaviest coffee and alcohol drinkers, and reported psychological symptoms most often.”

      The most common reasons cited for work-related stress included: high demand, time pressure, responsibilities, anxious temperament, financial insecurity, dangerous workplace, employee supervision, personal conflicts, difficult working conditions, and traffic.

      More studies examining the correlation between work-related stress and cancer are crucial moving forward, the authors noted.

      “While overreporting of stress cannot be fully ruled out, these associations, if substantial, would bear public health significance. Prospective studies building on detailed stress assessment protocols considering all sources and changes over the career are necessary.”

      _____________________________________________________________________________

      Blanc-Lapierre A, Rousseau MC, Weiss D, et al. Lifetime report of perceived stress at work and cancer among men: A case-control study in Montreal, Canada. Prev Med. 2017;96:28-35. doi: 10.1016/j.ypmed.2016.12.004.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
      Man standing in front of Oncology Nursing News-branded backdrop
      a man wearing a suit and tie in front of a green screen with the ONN logo
      Brenda Martone
      Arash Rezazadeh Kalebasty
      Leapman
      Related Content

      Graphic that resembles a stamp of approval reading "FDA Approved"

      Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

      Bridget Hoyt
      June 11th 2025
      Article

      The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Anatomical graphic of a person with a tumor in their left lung

      Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC

      Chris Ryan
      June 4th 2025
      Article

      Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      Line illustration of lungs with a tumor in the left lung

      Sevabertinib Given FDA Priority Review for HER2+ NSCLC

      Bridget Hoyt
      May 29th 2025
      Article

      The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

      Related Content

      Graphic that resembles a stamp of approval reading "FDA Approved"

      Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer

      Bridget Hoyt
      June 11th 2025
      Article

      The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.


      The Vitals

      Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

      Lindsay Fischer
      November 15th 2023
      Podcast

      Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.


      Anatomical graphic of a person with a tumor in their left lung

      Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC

      Chris Ryan
      June 4th 2025
      Article

      Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      Line illustration of lungs with a tumor in the left lung

      Sevabertinib Given FDA Priority Review for HER2+ NSCLC

      Bridget Hoyt
      May 29th 2025
      Article

      The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

      Latest Conference Coverage

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      Olanzapine May Reduce Nausea, Vomiting From Radiation

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.